指南与共识骨质疏松与钙磷/甲状旁腺肥胖与代谢综合征

维生素D预防疾病:内分泌学会临床实践指南

Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline.
指南 / 共识 · J Clin Endocrinol Metab · 2024-01-01

该指南由多学科专家组制定,针对无明确维生素D治疗或25(OH)D检测指征的人群,提出经验性补充维生素D的建议。推荐1-18岁儿童青少年、75岁以上老年人、孕妇及高风险糖尿病前期人群经验性补充维生素D;反对健康成人(<75岁)超过DRI补充及常规检测25(OH)D。

要点

  • 建议(弱推荐)1-18岁儿童青少年经验性补充维生素D以预防佝偻病并可能降低呼吸道感染风险。
  • 建议(弱推荐)75岁及以上老年人经验性补充维生素D以可能降低死亡风险。
  • 建议(弱推荐)孕妇经验性补充维生素D以可能降低子痫前期、宫内死亡、早产、小于胎龄儿及新生儿死亡风险。

核心结论

  • 专家组建议(弱推荐)对1-18岁儿童青少年、75岁以上老年人、孕妇及高风险糖尿病前期人群经验性补充维生素D。
  • 基于缺乏支持性临床试验证据,专家组建议(弱推荐)反对在无明确指征时常规检测25(OH)D。
  • 这些推荐不替代当前维生素D的DRI,也不适用于已有明确维生素D治疗或25(OH)D检测指征的人群。

研究设计与样本

  • 多学科专家组(包括临床专家、指南方法学专家和系统文献综述专家)确定并优先排序14个临床相关问题。
  • 优先纳入一般人群(无明确维生素D治疗或25(OH)D检测指征)的随机安慰剂对照试验,评估整个生命周期经验性维生素D补充的效果,以及特定情况(妊娠和糖尿病前期)。
  • 经验性补充定义为:维生素D摄入量超过膳食参考摄入量(DRI)且未检测25(OH)D。
  • 系统综述检索电子数据库,使用GRADE方法评估证据确定性并指导推荐。

主要发现

  • 纳入临床试验中维生素D剂量差异很大,且许多试验参与者被允许继续使用自身含维生素D的补充剂,因此所考虑人群的经验性补充最佳剂量仍不明确。
  • 未发现临床试验证据支持在一般人群、肥胖或深肤色人群中进行常规25(OH)D筛查,也无明确证据定义所考虑人群预防疾病所需的最佳25(OH)D目标水平。

关键数值与推荐

  • 建议(弱推荐)1-18岁儿童青少年经验性补充维生素D以预防营养性佝偻病,并因其可能降低呼吸道感染风险。
  • 建议(弱推荐)75岁及以上老年人经验性补充维生素D,因其可能降低死亡风险。
  • 建议(弱推荐)孕妇经验性补充维生素D,因其可能降低子痫前期、宫内死亡、早产、小于胎龄儿出生及新生儿死亡风险。
  • 建议(弱推荐)高风险糖尿病前期人群经验性补充维生素D,因其可能减少进展为糖尿病。
  • 建议(弱推荐)反对健康成人(<75岁)超过当前DRI经验性补充维生素D以降低疾病风险。

临床怎么用

  • 对于50岁以上非妊娠且有维生素D指征者,专家组建议(弱推荐)通过每日给予维生素D补充,而非间歇性使用高剂量。
  • 经验性补充可通过强化食品和含维生素D补充剂的组合实现,因天然富含维生素D的食物来源稀少。
  • 这些推荐不替代当前维生素D的DRI,也不适用于已有明确维生素D治疗或25(OH)D检测指征的人群。

局限性

  • 纳入临床试验中维生素D剂量差异很大,且许多试验参与者被允许继续使用自身含维生素D的补充剂,导致所考虑人群的经验性补充最佳剂量仍不明确。
  • 未发现临床试验证据支持在一般人群、肥胖或深肤色人群中进行常规25(OH)D筛查,也无明确证据定义所考虑人群预防疾病所需的最佳25(OH)D目标水平。
  • 需要进一步研究以确定特定健康获益的最佳25(OH)D水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Numerous studies demonstrate associations between serum concentrations of 25-hydroxyvitamin D (25[OH]D) and a variety of common disorders, including musculoskeletal, metabolic, cardiovascular, malignant, autoimmune, and infectious diseases. Although a causal link between serum 25(OH)D concentrations and many disorders has not been clearly established, these associations have led to widespread supplementation with vitamin D and increased laboratory testing for 25(OH)D in the general population. The benefit-risk ratio of this increase in vitamin D use is not clear, and the optimal vitamin D intake and the role of testing for 25(OH)D for disease prevention remain uncertain. OBJECTIVE: To develop clinical guidelines for the use of vitamin D (cholecalciferol [vitamin D3] or ergocalciferol [vitamin D2]) to lower the risk of disease in individuals without established indications for vitamin D treatment or 25(OH)D testing. METHODS: A multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 14 clinically relevant questions related to the use of vitamin D and 25(OH)D testing to lower the risk of disease. The panel prioritized randomized placebo-controlled trials in general populations (without an established indication for vitamin D treatment or 25[OH]D testing), evaluating the effects of empiric vitamin D administration throughout the lifespan, as well as in select conditions (pregnancy and prediabetes). The panel defined "empiric supplementation" as vitamin D intake that (a) exceeds the Dietary Reference Intakes (DRI) and (b) is implemented without testing for 25(OH)D. Systematic reviews queried electronic databases for publications related to these 14 clinical questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and guide recommendations. The approach incorporated perspectives from a patient representative and considered patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations. The process to develop this clinical guideline did not use a risk assessment framework and was not designed to replace current DRI for vitamin D. RESULTS: The panel suggests empiric vitamin D supplementation for children and adolescents aged 1 to 18 years to prevent nutritional rickets and because of its potential to lower the risk of respiratory tract infections; for those aged 75 years and older because of its potential to lower the risk of mortality; for those who are pregnant because of its potential to lower the risk of preeclampsia, intra-uterine mortality, preterm birth, small-for-gestational-age birth, and neonatal mortality; and for those with high-risk prediabetes because of its potential to reduce progression to diabetes. Because the vitamin D doses in the included clinical trials varied considerably and many trial participants were allowed to continue their own vitamin D-containing supplements, the optimal doses for empiric vitamin D supplementation remain unclear for the populations considered. For nonpregnant people older than 50 years for whom vitamin D is indicated, the panel suggests supplementation via daily administration of vitamin D, rather than intermittent use of high doses. The panel suggests against empiric vitamin D supplementation above the current DRI to lower the risk of disease in healthy adults younger than 75 years. No clinical trial evidence was found to support routine screening for 25(OH)D in the general population, nor in those with obesity or dark complexion, and there was no clear evidence defining the optimal target level of 25(OH)D required for disease prevention in the populations considered; thus, the panel suggests against routine 25(OH)D testing in all populations considered. The panel judged that, in most situations, empiric vitamin D supplementation is inexpensive, feasible, acceptable to both healthy individuals and health care professionals, and has no negative effect on health equity. CONCLUSION: The panel suggests empiric vitamin D for those aged 1 to 18 years and adults over 75 years of age, those who are pregnant, and those with high-risk prediabetes. Due to the scarcity of natural food sources rich in vitamin D, empiric supplementation can be achieved through a combination of fortified foods and supplements that contain vitamin D. Based on the absence of supportive clinical trial evidence, the panel suggests against routine 25(OH)D testing in the absence of established indications. These recommendations are not meant to replace the current DRIs for vitamin D, nor do they apply to people with established indications for vitamin D treatment or 25(OH)D testing. Further research is needed to determine optimal 25(OH)D levels for specific health benefits.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024. PMID: 38828931. doi:10.1210/clinem/dgae290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。